Baricitinib (Olumiant™): Now also available in the USA

Baricitinib (Olumiant™): Now also available in the USA

Baricitinib was first approved in the EU in February 2017 for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA);[1] this was followed shortly after by an approval in Japan in July of the same year.[2] Almost a year later, this Janus Kinase (JAK) inhibitor was approved by the US FDA in June 2018.[3] Continue reading “Baricitinib (Olumiant™): Now also available in the USA”

Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis

Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis

The recent first global approval of guselkumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis”

Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema

Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema

The recent first global approval of dupilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema”